Company profile: Pattern Bioscience
1.1 - Company Overview
Company description
- Provider of biotech diagnostic solutions to combat antibiotic resistance, including Digital Culture Technology, a single-cell analysis platform using digital cell reactors and machine learning to rapidly diagnose complex bacterial infections and determine antibiotic response without traditional culture, and the Pneumonia Action Panel for fast, comprehensive pathogen identification and susceptibility in hospitalized severe pneumonia.
Products and services
- Antibiotic Resistance Diagnostics: Biotech diagnostic service combating antibiotic resistance by rapidly diagnosing complex bacterial infections and determining antibiotic response using digital cell reactors with machine learning
- Digital Culture™ Technology: Single-cell platform that uses digital cell reactors with machine learning to rapidly diagnose complex bacterial infections and determine antibiotic response without traditional culture steps
- Pneumonia Action Panel: Digital Culture–based diagnostic test delivering fast, comprehensive pathogen identification and antibiotic susceptibility information for patients hospitalized with severe pneumonia
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pattern Bioscience
Ansun BioPharma
HQ: United States
Website
- Description: Provider of host-directed antivirals and solid tumor therapies. Offers DAS181, a recombinant sialidase that removes sialic acids from respiratory epithelial cells to block viral entry and treat parainfluenza and influenza. Develops multi-modality platforms targeting tumor and immune cells to prevent immune escape and restore tumor surveillance, including oncolytic viruses, bispecific antibodies, and CAR-NK/γδ T cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ansun BioPharma company profile →
Resistell
HQ: Switzerland
Website
- Description: Provider of antibiotic resistance testing via Phenotech Multistar, an ultra-rapid Antibiotic Susceptibility Testing (AST) platform using nanomotion technology to deliver results in 2 hours independent of bacterial growth, and Phenotech Research, a research device measuring nanoscale cellular vibrations to study growth phenotypes and provide rapid test results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resistell company profile →
Eiger BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eiger BioPharmaceuticals company profile →
ANA Therapeutics
HQ: United States
Website
- Description: Provider of biotech therapeutics developing a novel coronavirus vaccine and niclosamide-based treatments to enable medical practitioners to treat patients with COVID-19; founded in 2020 and headquartered in Foster City, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ANA Therapeutics company profile →
Achaogen
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, discovering and developing broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achaogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pattern Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pattern Bioscience
2.2 - Growth funds investing in similar companies to Pattern Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pattern Bioscience
4.2 - Public trading comparable groups for Pattern Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →